Qulipta (atogepant) is AbbVie's once-daily oral CGRP receptor antagonist indicated for the preventive treatment of migraine in adults.
Competing Products
AbbVie Inc., founded on April 10, 2012, is a biopharmaceutical company headquartered in North Chicago, Illinois. The company's core mission is to discover, develop, manufacture, and sell innovative pharmaceuticals that address complex health conditions. AbbVie's product portfolio includes Humira for autoimmune diseases, Skyrizi for plaque psoriasis and Crohn's disease, Rinvoq for rheumatoid arthritis and ulcerative colitis, and Imbruvica for cancer treatments. The company serves over 170 countries worldwide, focusing on improving patient outcomes through advanced medical therapies.
Key figures at AbbVie include Richard A. Gonzalez, the chairman and CEO, and Robert Michael, the president and COO. The company is publicly traded on the NYSE under the ticker ABBV and is a component of both the S&P 100 and S&P 500 indices. AbbVie has achieved significant milestones, including the widespread adoption of its flagship drug Humira, which has become one of the best-selling pharmaceuticals globally. The company's impact is profound, contributing to advancements in treating various chronic and life-threatening conditions, thereby enhancing the quality of life for millions of patients worldwide.
AbbVie - Quick Facts
Who are AbbVie's competitors?
Companies similar to AbbVie include Bristol Myers Squibb, Cristália, Enveda Biosciences and Galderma.
When was AbbVie founded?
AbbVie was founded in 2013.
Where is AbbVie's headquarters located?
AbbVie's headquarters is located in North Chicago, IL, US.
When was AbbVie's last funding round?
AbbVie's most recent funding round was for $250k (USD) in March 2023.
